Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 15/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 14/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098193 | 1.00 | ITGA4 (0.49) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7516096 | 1.00 | ITGA4 (0.49) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7098766 | 0.88 | ITGA4 (0.55) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7098769 | 0.88 | ITGA4 (0.55) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7101131 | 0.88 | ITGB1 (0.50) | ITGA4ITGB1ITGB7 | |
| SCHEMBL7101134 | 0.88 | ITGB1 (0.50) | ITGA4ITGB1ITGB7 | |
| SCHEMBL7098565 | 0.88 | NPSR1 (0.44) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7098569 | 0.88 | NPSR1 (0.44) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7102696 | 0.85 | ITGA4 (0.47) | ITGA4ITGB1MEN1KMT2ANPSR1 | |
| SCHEMBL7098693 | 0.85 | NPSR1 (0.52) | ITGA4ITGB1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | claimed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ITGA4 8/4885ITGB1 3/4885MEN1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.